<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1982">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390139</url>
  </required_header>
  <id_info>
    <org_study_id>BST-COVID-01</org_study_id>
    <nct_id>NCT04390139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19</brief_title>
  <acronym>COVIDMES</acronym>
  <official_title>A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, parallel, two-arms clinical trial to assess the efficacy and safety
      of 2 infusions of Wharton-Jelly mesenchymal stromal cells (day 1 and day 3, endovenously at
      1E6cells/Kg per dose) in patients with moderate acute respiratory distress syndrome (ARDS)
      secondary to SARS-CoV-2 infection. Follow-up will be established on days 3, 5, 7, 14, 21, and
      28. Long term follow-up will be performed at 3, 6 and 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blind, randomized, parallel, placebo-controlled pilot clinical
      trial to assess the efficacy and safety of two infusions of Wharton Jelly mesenchymal stromal
      cells (WJ-MSC) in patients with moderate acute respiratory distress syndrome (ARDS) secondary
      to SARS-CoV-2 infection. The study will enroll 30 patients who after signing the informed
      consent will be checked for inclusion and exclusion criteria. Patients will then be
      randomized (1:1) to one of the 2 treatment arms: Treatment A WJ-MSC/WJ-MSC; Treatment B
      Placebo/ Placebo. The 2 infusions will be administered endovenously on day 1 (D1) and on D3.
      Thereafter, patients will be followed-up on days 3, 5, 7, 14, 21, and 28 Once the study is
      completed, controls will be established at 3 months, 6 months and 12 months as long-term
      follow-up.

      The study treatments (A or B) will be added on top of the Standard of Care treatment
      prescribed by the attending physician. Each dose of MSC-WJ will consist of the intravenous
      administration of 1E6cells/Kg.

      Recruitment will be competitive for the centers participating in the study. A Data Safety and
      Monitoring Board (DSMB) will be established to review safety and efficacy along the trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality at day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of patients who died, by treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of WJ-MSC</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of patients with treatment-emergent adverse events, by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for treatment with rescue medication</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of patients who, after the start of treatment, required rescue medication, by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need and duration of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days that the patient requires invasive mechanical ventilation from the start of treatment to day +28, by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Day 28</time_frame>
    <description>Days after treatment in which the patient remains alive and free of invasive mechanical ventilation, per treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of PaO2 / FiO2 ratio</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation of the oxygenation index (PaO2 / FiO2) with respect to the baseline value, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the SOFA index</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation of the score of the Sequential Organ Failure Assessment (SOFA) Index with respect to the baseline value, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the APACHE II score</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation of Acute Physiology and Chronic Health disease Classification System II (APACHE II) score, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Day 28</time_frame>
    <description>Days of stay in the ICU from the day of admission until discharge to day 28, or date of death if earlier, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of markers of immune response (leucocyte count, neutrophils)</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation in the count and percentage of leukocytes and neutrophils, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of WJ-MSC administration</measure>
    <time_frame>Day 28</time_frame>
    <description>Feasibility will be evaluated by the time elapsed from the request of the treatment by the hospital center until the delivery date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of WJ-MSC administration</measure>
    <time_frame>Day 28</time_frame>
    <description>Feasibility will be evaluated by the number of patients treated within 2 days of the request for treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of disease biomarker: polymerase chain reaction (RT-PCR)</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation in the values of the biomarker, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of disease biomarker: lactate dehydrogenase (LDH)</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation in the values of the biomarker, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of disease biomarker: D-dimer</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation in the values of the biomarker, by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of disease biomarker: Ferritin</measure>
    <time_frame>Day 28</time_frame>
    <description>Variation in the values of the biomarker, by treatment group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of subpopulations of lymphocytes and immunoglobulins</measure>
    <time_frame>Day 28</time_frame>
    <description>Blood sample analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of the in vitro response of the receptor lymphocytes</measure>
    <time_frame>Day 28</time_frame>
    <description>In vitro response will be assessed using commercial viral antigens (Miltenyi Biotech)</description>
  </other_outcome>
  <other_outcome>
    <measure>Study of reactivity against SARS-CoV-2 peptides</measure>
    <time_frame>Day 28</time_frame>
    <description>Reactivity will be assessed using ELISPOT</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunophenotypic study of memory cells in response to SARS-CoV-2 peptides</measure>
    <time_frame>Day 28</time_frame>
    <description>Blood sample analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic variability of patient's genotype in response to treatment</measure>
    <time_frame>Day 28</time_frame>
    <description>Blood sample analysis for the patient's genomic sequencing</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic variability of the SARS-CoV-2 genotype in response to treatment</measure>
    <time_frame>Day 28</time_frame>
    <description>Genomic sequencing of the SARS-CoV-2 in a nasopharyngeal sample</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Adult Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wharton-Jelly mesenchymal stromal cells on D1 and D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo on D1 and D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-UMC-BETA</intervention_name>
    <description>Administration on top of the standard administered treatment</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>WJ-MSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration on top of the standard administered treatment</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive PCR fpr SARS-CoV-2

          2. Intensive Care Unit admission for less than 3 days

          3. Moderate acute respiratory distress (Berlin criteria definition with 100 mmHg &lt;
             PaO2/FiO2 ≤ 200 mmHg)

          4. Male or female, aged 18 to 70 years old

          5. Signed informed consent by the patient or by a legal representative (in this case, can
             be obtained by phone, although it must be confirmed in writing later, accepted by
             email)

        Exclusion Criteria:

          1. Expected survival less than 3 days

          2. Treatment with immunosuppressive drugs (tocilizumab, sarilumab) with corticosteroids
             being allowed

          3. Neoplastic disease either active or without complete remission

          4. Immunosuppressed patients (except treatment with corticosteroids for respiratory
             distress)

          5. Pregnant or lactating women

          6. Participation in another clinical trial with an experimental drug in the last 30 days

          7. Other pathologies that, in medical judgment, contraindicate participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Torres, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Coll, MD</last_name>
    <phone>34935570500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joaquin Delgadillo, MD, PhD</last_name>
    <email>jadelgadillo@bst.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Mañez, MD, PhD</last_name>
      <phone>+34932607646</phone>
      <email>rmanez@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Rafael Mañez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Daniel Gumucio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Moreno Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Via, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Trenado, MD, PhD</last_name>
      <phone>+34937365050</phone>
      <phone_ext>18050</phone_ext>
      <email>jtrenado@mutuaterrassa.es</email>
    </contact>
    <investigator>
      <last_name>Josep Trenado, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Marin-Corral, MD, PhD</last_name>
      <phone>+34 932483000</phone>
      <email>jmarincorral@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Judith Marin-Corral, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramon Adalia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricard Ferrer, MD, PhD</last_name>
      <phone>+34 932746209</phone>
      <email>r.ferrer@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Ricard Ferrer, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoni torres, MD, PhD</last_name>
      <phone>+34 932275549</phone>
      <email>ATORRES@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Antoni Torres, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Castro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.clinicbarcelona.org</url>
    <description>Hospital Clínic de Barcelona</description>
  </link>
  <link>
    <url>http://www.vallhebron.com</url>
    <description>Hospital Vall d'Hebron</description>
  </link>
  <link>
    <url>http://www.parcdesalutmar.cat</url>
    <description>Hospital del Mar</description>
  </link>
  <link>
    <url>http://www.mutuaterrassa.com</url>
    <description>Mútua de Terrassa</description>
  </link>
  <link>
    <url>http://bellvitgehospital.cat</url>
    <description>Hospital de Bellvitge</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

